PubRank

Michael S Diamond

Author PubWeight™ 290.07‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc Natl Acad Sci U S A 2006 8.27
2 Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science 2008 7.87
3 Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med 2005 5.09
4 Herpesvirus latency confers symbiotic protection from bacterial infection. Nature 2007 4.27
5 Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J Virol 2005 3.59
6 Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature 2005 3.51
7 2'-O methylation of the viral mRNA cap evades host restriction by IFIT family members. Nature 2010 3.49
8 The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 2010 3.48
9 Role of CD8+ T cells in control of West Nile virus infection. J Virol 2004 3.40
10 Neuronal CXCL10 directs CD8+ T-cell recruitment and control of West Nile virus encephalitis. J Virol 2005 3.31
11 Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol 2008 3.27
12 The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 2007 3.25
13 Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J Virol 2006 3.23
14 Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog 2010 3.16
15 Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion. J Virol 2006 3.15
16 PKR and RNase L contribute to protection against lethal West Nile Virus infection by controlling early viral spread in the periphery and replication in neurons. J Virol 2006 3.13
17 Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol 2007 2.89
18 Ribose 2'-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5. Nat Immunol 2011 2.85
19 Toll-like receptor 3 has a protective role against West Nile virus infection. J Virol 2008 2.62
20 Six RNA viruses and forty-one hosts: viral small RNAs and modulation of small RNA repertoires in vertebrate and invertebrate systems. PLoS Pathog 2010 2.62
21 IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. Nat Immunol 2012 2.62
22 Crystal structure of the West Nile virus envelope glycoprotein. J Virol 2006 2.61
23 A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Virology 2005 2.60
24 Resistance to alpha/beta interferon is a determinant of West Nile virus replication fitness and virulence. J Virol 2006 2.57
25 Cell-specific IRF-3 responses protect against West Nile virus infection by interferon-dependent and -independent mechanisms. PLoS Pathog 2007 2.54
26 CD4+ T-cell responses are required for clearance of West Nile virus from the central nervous system. J Virol 2006 2.44
27 Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A 2012 2.42
28 West Nile virus infection and immunity. Nat Rev Microbiol 2013 2.40
29 IPS-1 is essential for the control of West Nile virus infection and immunity. PLoS Pathog 2010 2.39
30 CD8+ T cells require perforin to clear West Nile virus from infected neurons. J Virol 2006 2.31
31 Induction of epitope-specific neutralizing antibodies against West Nile virus. J Virol 2007 2.30
32 Infection and injury of neurons by West Nile encephalitis virus. J Virol 2003 2.25
33 Tregs control the development of symptomatic West Nile virus infection in humans and mice. J Clin Invest 2009 2.18
34 Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe 2008 2.16
35 Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol 2010 2.14
36 Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice. J Virol 2003 2.13
37 Protective immune responses against West Nile virus are primed by distinct complement activation pathways. J Exp Med 2006 2.11
38 The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog 2010 2.03
39 Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog 2008 2.00
40 Secreted NS1 of dengue virus attaches to the surface of cells via interactions with heparan sulfate and chondroitin sulfate E. PLoS Pathog 2007 1.97
41 Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo. J Virol 2005 1.97
42 West Nile virus nonstructural protein NS1 inhibits complement activation by binding the regulatory protein factor H. Proc Natl Acad Sci U S A 2006 1.96
43 Induction of IFN-beta and the innate antiviral response in myeloid cells occurs through an IPS-1-dependent signal that does not require IRF-3 and IRF-7. PLoS Pathog 2009 1.95
44 In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis 2011 1.92
45 Interferon regulatory factor IRF-7 induces the antiviral alpha interferon response and protects against lethal West Nile virus infection. J Virol 2008 1.92
46 Antibodies against West Nile Virus nonstructural protein NS1 prevent lethal infection through Fc gamma receptor-dependent and -independent mechanisms. J Virol 2006 1.91
47 Antigen-specific cytotoxic T lymphocytes protect against lethal West Nile virus encephalitis. Eur J Immunol 2007 1.89
48 Caspase 3-dependent cell death of neurons contributes to the pathogenesis of West Nile virus encephalitis. J Virol 2006 1.86
49 Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody. EMBO J 2009 1.85
50 Gamma interferon plays a crucial early antiviral role in protection against West Nile virus infection. J Virol 2006 1.84
51 Interferon-induced Ifit2/ISG54 protects mice from lethal VSV neuropathogenesis. PLoS Pathog 2012 1.84
52 Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters. J Infect Dis 2006 1.84
53 West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibody. Proc Natl Acad Sci U S A 2006 1.83
54 Antagonism of the complement component C4 by flavivirus nonstructural protein NS1. J Exp Med 2010 1.76
55 Dengue structure differs at the temperatures of its human and mosquito hosts. Proc Natl Acad Sci U S A 2013 1.75
56 Complement activation is required for induction of a protective antibody response against West Nile virus infection. J Virol 2005 1.75
57 Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus. J Virol 2005 1.72
58 A viral RNA structural element alters host recognition of nonself RNA. Science 2014 1.71
59 Axonal transport mediates West Nile virus entry into the central nervous system and induces acute flaccid paralysis. Proc Natl Acad Sci U S A 2007 1.71
60 Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection. Expert Rev Mol Med 2008 1.67
61 IRF-3, IRF-5, and IRF-7 coordinately regulate the type I IFN response in myeloid dendritic cells downstream of MAVS signaling. PLoS Pathog 2013 1.67
62 Human monoclonal antibodies against West Nile virus induced by natural infection neutralize at a postattachment step. J Virol 2009 1.65
63 2'-O methylation of the viral mRNA cap by West Nile virus evades ifit1-dependent and -independent mechanisms of host restriction in vivo. PLoS Pathog 2012 1.62
64 Nondegradative role of Atg5-Atg12/ Atg16L1 autophagy protein complex in antiviral activity of interferon gamma. Cell Host Microbe 2012 1.61
65 CXCR3 mediates region-specific antiviral T cell trafficking within the central nervous system during West Nile virus encephalitis. J Immunol 2008 1.61
66 CXCR4 antagonism increases T cell trafficking in the central nervous system and improves survival from West Nile virus encephalitis. Proc Natl Acad Sci U S A 2008 1.60
67 Genotype-specific neutralization and protection by antibodies against dengue virus type 3. J Virol 2010 1.58
68 Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354. Proc Natl Acad Sci U S A 2010 1.57
69 Differential innate immune response programs in neuronal subtypes determine susceptibility to infection in the brain by positive-stranded RNA viruses. Nat Med 2013 1.55
70 Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants. J Exp Med 2011 1.53
71 An infectious West Nile virus that expresses a GFP reporter gene. Virology 2005 1.51
72 Cleavage targets and the D-arginine-based inhibitors of the West Nile virus NS3 processing proteinase. Biochem J 2006 1.49
73 Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step. J Virol 2011 1.49
74 Tumor necrosis factor alpha protects against lethal West Nile virus infection by promoting trafficking of mononuclear leukocytes into the central nervous system. J Virol 2008 1.48
75 Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus. PLoS Pathog 2013 1.47
76 Endogenous MHC-related protein 1 is transiently expressed on the plasma membrane in a conformation that activates mucosal-associated invariant T cells. J Immunol 2011 1.47
77 Binding of flavivirus nonstructural protein NS1 to C4b binding protein modulates complement activation. J Immunol 2011 1.45
78 Evidence for a genetic and physical interaction between nonstructural proteins NS1 and NS4B that modulates replication of West Nile virus. J Virol 2012 1.43
79 The essential, nonredundant roles of RIG-I and MDA5 in detecting and controlling West Nile virus infection. J Virol 2013 1.42
80 Enveloped viruses disable innate immune responses in dendritic cells by direct activation of TAM receptors. Cell Host Microbe 2013 1.42
81 A therapeutic antibody against west nile virus neutralizes infection by blocking fusion within endosomes. PLoS Pathog 2009 1.41
82 The RIG-I-like receptor LGP2 controls CD8(+) T cell survival and fitness. Immunity 2012 1.39
83 The immune adaptor molecule SARM modulates tumor necrosis factor alpha production and microglia activation in the brainstem and restricts West Nile Virus pathogenesis. J Virol 2009 1.39
84 Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects. J Clin Invest 2017 1.39
85 The innate immune adaptor molecule MyD88 restricts West Nile virus replication and spread in neurons of the central nervous system. J Virol 2010 1.38
86 Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner. Cell Host Microbe 2007 1.37
87 Mosquito bite delivery of dengue virus enhances immunogenicity and pathogenesis in humanized mice. J Virol 2012 1.36
88 West Nile virus noncoding subgenomic RNA contributes to viral evasion of the type I interferon-mediated antiviral response. J Virol 2012 1.35
89 Early B-cell activation after West Nile virus infection requires alpha/beta interferon but not antigen receptor signaling. J Virol 2008 1.35
90 Antibody recognition of cell surface-associated NS1 triggers Fc-gamma receptor-mediated phagocytosis and clearance of West Nile Virus-infected cells. J Virol 2007 1.32
91 Structural basis of differential neutralization of DENV-1 genotypes by an antibody that recognizes a cryptic epitope. PLoS Pathog 2012 1.31
92 Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a hamster model. Antimicrob Agents Chemother 2007 1.30
93 Pathogenesis of flavivirus encephalitis. Adv Virus Res 2003 1.30
94 CD40-CD40 ligand interactions promote trafficking of CD8+ T cells into the brain and protection against West Nile virus encephalitis. J Virol 2007 1.30
95 Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus. Cell Host Microbe 2009 1.27
96 Chronic joint disease caused by persistent Chikungunya virus infection is controlled by the adaptive immune response. J Virol 2013 1.26
97 A temporal role of type I interferon signaling in CD8+ T cell maturation during acute West Nile virus infection. PLoS Pathog 2011 1.26
98 The utility of siRNA transcripts produced by RNA polymerase i in down regulating viral gene expression and replication of negative- and positive-strand RNA viruses. Virology 2003 1.25
99 Capturing a flavivirus pre-fusion intermediate. PLoS Pathog 2009 1.24
100 Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complement-dependent effector mechanisms. J Virol 2011 1.24
101 Beta interferon controls West Nile virus infection and pathogenesis in mice. J Virol 2011 1.23
102 Monoclonal antibody produced in plants efficiently treats West Nile virus infection in mice. Proc Natl Acad Sci U S A 2010 1.23
103 Fas ligand interactions contribute to CD8+ T-cell-mediated control of West Nile virus infection in the central nervous system. J Virol 2007 1.23
104 Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection. J Virol 2013 1.22
105 Actively replicating West Nile virus is resistant to cytoplasmic delivery of siRNA. Virol J 2005 1.21
106 The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein. MBio 2013 1.21
107 The interferon-inducible gene viperin restricts West Nile virus pathogenesis. J Virol 2011 1.20
108 Therapeutic efficacy of antibodies lacking Fcγ receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected]. PLoS Pathog 2013 1.20
109 West Nile virus: crossing the blood-brain barrier. Nat Med 2004 1.19
110 Single-chain HLA-A2 MHC trimers that incorporate an immundominant peptide elicit protective T cell immunity against lethal West Nile virus infection. J Immunol 2010 1.18
111 Propagation, quantification, detection, and storage of West Nile virus. Curr Protoc Microbiol 2013 1.18
112 The lectin pathway of complement activation contributes to protection from West Nile virus infection. Virology 2011 1.16
113 Structure and intracellular targeting of the SARS-coronavirus Orf7a accessory protein. Structure 2005 1.16
114 Spontaneous mutation of the Dock2 gene in Irf5-/- mice complicates interpretation of type I interferon production and antibody responses. Proc Natl Acad Sci U S A 2012 1.15
115 Degrees of maturity: the complex structure and biology of flaviviruses. Curr Opin Virol 2012 1.15
116 A short hairpin RNA screen of interferon-stimulated genes identifies a novel negative regulator of the cellular antiviral response. MBio 2013 1.13
117 Robust production of virus-like particles and monoclonal antibodies with geminiviral replicon vectors in lettuce. Plant Biotechnol J 2011 1.12
118 On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes. J Gen Virol 2009 1.11
119 Inhibitor of κB kinase epsilon (IKK(epsilon)), STAT1, and IFIT2 proteins define novel innate immune effector pathway against West Nile virus infection. J Biol Chem 2011 1.10
120 The naturally attenuated Kunjin strain of West Nile virus shows enhanced sensitivity to the host type I interferon response. J Virol 2011 1.10
121 Structural analyses at pseudo atomic resolution of Chikungunya virus and antibodies show mechanisms of neutralization. Elife 2013 1.10
122 The relative contribution of antibody and CD8+ T cells to vaccine immunity against West Nile encephalitis virus. Vaccine 2008 1.10
123 Critical role for interferon regulatory factor 3 (IRF-3) and IRF-7 in type I interferon-mediated control of murine norovirus replication. J Virol 2012 1.09
124 Interferon regulatory factor-1 (IRF-1) shapes both innate and CD8(+) T cell immune responses against West Nile virus infection. PLoS Pathog 2011 1.09
125 Fusion loop peptide of the West Nile virus envelope protein is essential for pathogenesis and is recognized by a therapeutic cross-reactive human monoclonal antibody. J Immunol 2009 1.05
126 Mutations of an antibody binding energy hot spot on domain III of the dengue 2 envelope glycoprotein exploited for neutralization escape. Virology 2010 1.05
127 Chikungunya virus infection results in higher and persistent viral replication in aged rhesus macaques due to defects in anti-viral immunity. PLoS Negl Trop Dis 2013 1.04
128 Translation efficiency determines differences in cellular infection among dengue virus type 2 strains. Virology 2003 1.04
129 RNA sensor-induced type I IFN prevents diabetes caused by a β cell-tropic virus in mice. J Clin Invest 2011 1.04
130 Pattern recognition receptor MDA5 modulates CD8+ T cell-dependent clearance of West Nile virus from the central nervous system. J Virol 2013 1.04
131 Cutting edge: independent roles for IRF-3 and IRF-7 in hematopoietic and nonhematopoietic cells during host response to Chikungunya infection. J Immunol 2012 1.04
132 Development and characterization of non-glycosylated E and NS1 mutant viruses as a potential candidate vaccine for West Nile virus. Vaccine 2009 1.03
133 Direct complement restriction of flavivirus infection requires glycan recognition by mannose-binding lectin. Cell Host Microbe 2010 1.03
134 N-linked glycosylation of dengue virus NS1 protein modulates secretion, cell-surface expression, hexamer stability, and interactions with human complement. Virology 2011 1.02
135 West Nile virus-induced acute flaccid paralysis is prevented by monoclonal antibody treatment when administered after infection of spinal cord neurons. J Neurovirol 2008 1.01
136 A role for Ifit2 in restricting West Nile virus infection in the brain. J Virol 2013 1.00
137 Identification of novel small-molecule inhibitors of West Nile virus infection. J Virol 2007 1.00
138 Development of resistance to passive therapy with a potently neutralizing humanized monoclonal antibody against West Nile virus. J Infect Dis 2009 0.99
139 A hydrogen peroxide-inactivated virus vaccine elicits humoral and cellular immunity and protects against lethal West Nile virus infection in aged mice. J Virol 2012 0.98
140 CD8+ T cells use TRAIL to restrict West Nile virus pathogenesis by controlling infection in neurons. J Virol 2012 0.98
141 Complement-mediated neutralization of dengue virus requires mannose-binding lectin. MBio 2011 0.97
142 Structural basis of Flavivirus NS1 assembly and antibody recognition. Proc Natl Acad Sci U S A 2014 0.97
143 Dengue virus neutralization is modulated by IgG antibody subclass and Fcgamma receptor subtype. Virology 2009 0.97
144 Human antibodies against dengue enhance dengue viral infectivity without suppressing type I interferon secretion in primary human monocytes. Virology 2010 0.96
145 A short N-terminal peptide motif on flavivirus nonstructural protein NS1 modulates cellular targeting and immune recognition. J Virol 2010 0.96
146 Immunological headgear: antiviral immune responses protect against neuroinvasive West Nile virus. Trends Mol Med 2008 0.96
147 Complement and its role in protection and pathogenesis of flavivirus infections. Vaccine 2008 0.96
148 Immune responses to West Nile virus infection in the central nervous system. Viruses 2012 0.95
149 Structural and functional characterization of an anti-West Nile virus monoclonal antibody and its single-chain variant produced in glycoengineered plants. Plant Biotechnol J 2014 0.93
150 Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex. Expert Rev Vaccines 2012 0.93
151 Complement modulates pathogenesis and antibody-dependent neutralization of West Nile virus infection through a C5-independent mechanism. Virology 2009 0.93
152 Distinguishing West Nile virus infection using a recombinant envelope protein with mutations in the conserved fusion-loop. BMC Infect Dis 2014 0.93
153 Measure and countermeasure: type I IFN (IFN-alpha/beta) antiviral response against West Nile virus. J Innate Immun 2009 0.92
154 Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature. Virology 2011 0.92
155 A fusion-loop antibody enhances the infectious properties of immature flavivirus particles. J Virol 2011 0.92
156 Global analyses revealed age-related alterations in innate immune responses after stimulation of pathogen recognition receptors. Aging Cell 2015 0.92
157 Differential replication of pathogenic and nonpathogenic strains of West Nile virus within astrocytes. J Virol 2012 0.91
158 TNF-alpha-dependent regulation of CXCR3 expression modulates neuronal survival during West Nile virus encephalitis. J Neuroimmunol 2010 0.91
159 Protection by immunoglobulin dual-affinity retargeting antibodies against dengue virus. J Virol 2013 0.90
160 Antibodies against the envelope glycoprotein promote infectivity of immature dengue virus serotype 2. PLoS One 2012 0.90
161 Neurotropic arboviruses induce interferon regulatory factor 3-mediated neuronal responses that are cytoprotective, interferon independent, and inhibited by Western equine encephalitis virus capsid. J Virol 2012 0.89
162 Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice. Virol J 2010 0.89
163 A novel computer algorithm improves antibody epitope prediction using affinity-selected mimotopes: a case study using monoclonal antibodies against the West Nile virus E protein. Mol Immunol 2008 0.88
164 A CRISPR screen defines a signal peptide processing pathway required by flaviviruses. Nature 2016 0.87
165 Defining the levels of secreted non-structural protein NS1 after West Nile virus infection in cell culture and mice. J Med Virol 2008 0.87
166 The Fc region of an antibody impacts the neutralization of West Nile viruses in different maturation states. J Virol 2013 0.86
167 The molecular basis of antibody-mediated neutralization of West Nile virus. Expert Opin Biol Ther 2007 0.82
168 Antibody responses in humans infected with newly emerging strains of West Nile Virus in Europe. PLoS One 2013 0.82
169 A novel T-cell receptor mimic defines dendritic cells that present an immunodominant West Nile virus epitope in mice. Eur J Immunol 2014 0.82
170 The transmembrane domain of the severe acute respiratory syndrome coronavirus ORF7b protein is necessary and sufficient for its retention in the Golgi complex. J Virol 2008 0.82
171 Corrigendum: Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity. Nature 2015 0.81
172 Structure, expression, and intracellular localization of the SARS-CoV accessory proteins 7a and 7b. Adv Exp Med Biol 2006 0.81
173 A cross-protective mAb recognizes a novel epitope within the flavivirus NS1 protein. J Gen Virol 2011 0.81
174 Complex phenotypes in mosquitoes and mice associated with neutralization escape of a Dengue virus type 1 monoclonal antibody. Virology 2012 0.81
175 Hepatitis C virus infection upregulates CD55 expression on the hepatocyte surface and promotes association with virus particles. J Virol 2013 0.80
176 Modified mRNA Vaccines Protect against Zika Virus Infection. Cell 2017 0.79
177 Loss of DAP12 and FcRγ drives exaggerated IL-12 production and CD8(+) T cell response by CCR2(+) Mo-DCs. PLoS One 2013 0.78
178 Regional astrocyte IFN signaling restricts pathogenesis during neurotropic viral infection. J Clin Invest 2017 0.77
179 A tetravalent dengue nanoparticle stimulates antibody production in mice. J Nanobiotechnology 2012 0.75
180 Correction: Zika virus has oncolytic activity against glioblastoma stem cells. J Exp Med 2017 0.75
181 [West Nile virus. II. Immunopathophysiology in humans]. Med Sci (Paris) 2011 0.75